You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-CD47

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

Not yet recruiting
  • Ovarian Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 19, 2022

Relapsed/Refractory Lymphoma Trial in Beijing (Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection)

Recruiting
  • Relapsed/Refractory Lymphoma
  • Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciense
Jan 10, 2022

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)

Not yet recruiting
  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jul 17, 2023

Advanced Solid Tumors Trial in Beijing (HX009)

Active, not recruiting
  • Advanced Solid Tumors
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciense
Feb 7, 2023

Myelodysplastic Syndrome Trial in Suzhou (AK117, Azacitidine)

Recruiting
  • Myelodysplastic Syndrome
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 21, 2021

Acute Myeloid Leukemia Trial in Hangzhou (AK117, Azacitidine)

Recruiting
  • Acute Myeloid Leukemia
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，Zhejiang University School of Medi
Jul 21, 2021

Advanced Malignant Tumors Trial in Hangzhou (AK112, AK117, Chemotherapy)

Recruiting
  • Advanced Malignant Tumors
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jan 27, 2022

Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)

Recruiting
  • Advanced Malignant Tumors
  • Shanghai, China
    Shanghai Renji Hospital
Aug 9, 2022

Advanced Malignant Tumors Trial in Hangzhou (AK112, AK117, Carboplatin)

Recruiting
  • Advanced Malignant Tumors
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 10, 2022

Solid Tumor, Non-Hodgkin Lymphoma Trial in Shanghai, Hangzhou (Gentulizumab)

Recruiting
  • Solid Tumor
  • Non-Hodgkin Lymphoma
  • Shanghai, Shanghai, China
  • +1 more
Jan 21, 2022

Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma Trial in Stanford (Magrolimab, Pembrolizumab,

Recruiting
  • Hodgkin Lymphoma
  • +3 more
  • Stanford, California
    Stanford University
Jun 21, 2022

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Apr 10, 2023

Solid Tumor, Relapsed Solid Tumor, Refractory Tumor Trial in United States (STI-6643)

Recruiting
  • Solid Tumor
  • +2 more
  • STI-6643
  • San Diego, California
  • +4 more
Jun 30, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

Not yet recruiting
  • Advanced Solid Tumor
  • Refractory Non-Hodgkin Lymphoma
  • (no location specified)
May 28, 2023

Hematological Malignancy, Lymphoma Trial in Canton (SG2501)

Recruiting
  • Hematological Malignancy
  • Lymphoma
  • Canton, Ohio
    Gabrail Cancer Center Research, LLC
Aug 3, 2022

Advanced Malignant Tumor Trial in Guangzhou (BAT7104 injection)

Recruiting
  • Advanced Malignant Tumor
  • BAT7104 injection
  • Guangzhou, Guangdong, China
    Li Zhang
Mar 1, 2023

NHL, DLBCL, Non-hodgkin's Lymphoma Trial in United Kingdom, United States (AZD9150, Acalabrutinib, AZD6738)

Completed
  • NHL
  • +3 more
  • Los Angeles, California
  • +11 more
Aug 11, 2022

Cancer of the Colon Trial in Marseille (BLOOD AND TUMOR)

Recruiting
  • Cancer of the Colon
  • BLOOD AND TUMOR
  • Marseille, France
    Institut Paoli Calmettes
Jul 12, 2023

Advanced Malignant Tumors Lymphomas Trial in United States (IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody

Recruiting
  • Advanced Malignant Tumors Lymphomas
  • IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
  • Los Angeles, California
  • +3 more
Aug 23, 2022

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New

Recruiting
  • Mantle-cell Lymphoma
  • B Cell Chronic Lymphocytic Leukemia
    • Monza, MB, Italy
      Andrea Aroldi
    May 24, 2023

    Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

    Recruiting
    • Aggressive B-Cell Non-Hodgkin Lymphoma
    • +19 more
    • CD47 Antagonist ALX148
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Advanced Solid Tumor Trial in Kogarah (HX009)

    Active, not recruiting
    • Advanced Solid Tumor
    • Kogarah, New South Wales, Australia
      St George Private Hospital
    Jul 7, 2021

    Solid Tumor Trial in Beijing (SHR2150, Anti-Cancer Agent)

    Unknown status
    • Solid Tumor
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinese PLA General Hospital
    Oct 15, 2020